Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q2 2024 · 10-Q
Revenue$9.85M$9.85M−9.6% vs Q2 2023 Net Income-$1.09M-$1.09MN/M vs Q2 2023 EPS Diluted-$0.08-$0.08N/M vs Q2 2023 Operating Income-$1,026,688N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$862,838N/M Margins · derivedOperating margin-10.4%−10.6 pt vs Q2 2023
Net margin-11.0%−19.0 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 9, 2024 · 40 d after period end